AZNAstraZenecaSigning up patients
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Metastatic Castration-resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 670 (planned)
- Started
- May 4, 2026
- Main results expected
- Jun 4, 2029
- Fully finished
- Jun 6, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-Free Survival (rPFS)
Measured over: From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)
Overall Survival (OS)
Measured over: From randomization until death from any cause (up to approximately 33 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07611110 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC